MolecularMD Withdraws PMA for Leukemia CDx | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD and Ariad Pharmaceuticals today said that MolecularMD has withdrawn its premarket approval application to the US Food and Drug Administration for its BCR-ABL T315I Mutation Test.

MolecularMD's test detects the BCR-ABL T315I mutation in chronic myeloid leukemia and Philadephia-chromosome positive acute lymphoblastic leukemia patients and was intended as a companion diagnostic for Ariad's investigational BCR-ABL inhibitor, ponatinib, currently being reviewed by FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.